SAB-142 Phase 1 Data Shows C-Peptide Preservation and Improved Glycemic Control in Type 1 Diabetes
SABS has more than doubled off its 52-week low of $1.3.
Summary
SAB Biotherapeutics reported positive additional Phase 1 clinical data for its lead Type 1 Diabetes candidate, SAB-142, demonstrating C-peptide preservation and improved glycemic control without increased insulin use.
Key Events · Product Development and Regulatory · SABS
-
Positive Phase 1 T1D Data
Additional clinical and mechanistic data from the Phase 1 trial of SAB-142 in Type 1 Diabetes patients was presented.
-
C-Peptide Preservation
All four treated T1D participants showed C-peptide preservation, with three exhibiting a "super responder" profile, correlating with T cell exhaustion.
-
Improved Glycemic Control
Participants demonstrated an increase in mean Time in Range (TIR) from 73% at baseline to 85% at Day 120, without an increase in exogenous insulin use.
-
Favorable Safety Profile
The data showed sustained immunomodulation without immunodepletion, with mild, transient adverse events and no drug-related serious adverse events or serum sickness.
Analysis · SABS · Life Sciences
This 8-K filing provides significant positive clinical and mechanistic data from the Phase 1 trial of SAB-142, the company's lead candidate for Type 1 Diabetes. The findings of C-peptide preservation, a "super responder" profile in most participants, and improved glycemic control without increased exogenous insulin use are strong indicators of SAB-142's potential as a disease-modifying therapy. The data also reinforces a favorable safety profile with sustained immunomodulation without immunodepletion, differentiating it from existing treatments. This positive update de-risks the ongoing registrational Phase 2b SAFEGUARD trial and builds confidence in the program's future, which is crucial for a clinical-stage biopharmaceutical company. Investors should monitor the progress of the Phase 2b trial, with topline data expected in 2H 2027.
How filings like this one have moved
In the 30 days to Sep 22, 2026, 34.8% of the 1044 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SABS was trading at $3.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $194.1M. The 52-week trading range was $1.30 to $6.60. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.